- Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
- Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
- Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
Pharming Group NV (PHGN:BRN) closed at 1.10, 0.00% below its 52-week high of 1.10, set on Aug 26, 2022.
1.10Aug 26 20221.10Aug 26 2022
Markit short selling activity
|Market cap||789.14m EUR|
|EPS (TTM)||0.0407 |
Data delayed at least 15 minutes, as of Aug 26 2022.